Guidance for the clinical evaluation of traditional Chinese medicine-induced liver injuryIssued by China Food and Drug Administration
Acta Pharm Sin B
.
2019 May;9(3):648-658.
doi: 10.1016/j.apsb.2018.12.003.
Epub 2018 Dec 14.
Authors
Xiaohe Xiao
1
,
Jianyuan Tang
2
,
Yimin Mao
3
,
Xiuhui Li
4
,
Jiabo Wang
1
,
Chenghai Liu
5
,
Kewei Sun
6
,
Yong'an Ye
7
,
Zhengsheng Zou
8
,
Cheng Peng
9
,
Ling Yang
10
,
Yuming Guo
1
,
Zhaofang Bai
1
,
Tingting He
1
,
Jing Jing
1
,
Fengyi Li
11
,
Na An
2
Affiliations
1
China Military Institute of Chinese Medicine, Beijing 302 Hospital of China, Beijing 100039, China.
2
Center for Drug Evaluation, China Food and Drug Administration, Beijing 100022, China.
3
Renji Hospital of Shanghai Jiaotong University, Shanghai 200127, China.
4
Beijing Youan Hospital of Capital Medical University, Beijing 100069, China.
5
Shuguang Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai 200127, China.
6
First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Changsha 410007, China.
7
Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine, Beijing 100700, China.
8
Center for Non-infectious Liver Diseases, Beijing 302 Hospital of China, Beijing 100039, China.
9
College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China.
10
College of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
11
Center for Infectious Liver Diseases, Beijing 302 Hospital of China, Beijing 100039, China.
PMID:
31193760
PMCID:
PMC6543019
DOI:
10.1016/j.apsb.2018.12.003
No abstract available